FGF7P3: Potential Drug Target and Biomarker for Cancer and Neurodegenerative Diseases

Target Name: FGF7P3

NCBI ID: G654466

FGF7P3

Other Name(s): KGFLP2 | Fibroblast growth factor 7 pseudogene 3 | RP11-204M4.2 | fibroblast growth factor 7 pseudogene 3

FGF7P3: Potential Drug Target and Biomarker for Cancer and Neurodegenerative Diseases

FGF7P3 (KGFLP2), a protein encoded by the gene FGF7P3, is a member of the family of growth factors and is involved in several biological processes including cell growth, differentiation, and survival. The FGF7P3 gene has been identified as a potential drug target and a biomarker for several diseases, including cancer, neurodegenerative diseases, and developmental disorders.

The FGF7P3 gene is located on chromosome 16p13.2 and has a calculated gene length of 1,944 base pairs. The protein encoded by this gene has a molecular weight of 114.1 kDa and a predicted localization to the endoplasmic reticulum. FGF7P3 is a glycoprotein with a single transmembrane region and a N-terminal extracellular domain.

The FGF7P3 gene is involved in several biological processes, including cell growth, differentiation, and survival. It is a potent growth factor for various cell types, including neurons, glial cells, and epithelial cells. FGF7P3 signaling has been implicated in the development and progression of several diseases, including cancer, neurodegenerative diseases, and developmental disorders.

FGF7P3 has been identified as a potential drug target for several diseases, including cancer. cancer is a leading cause of death worldwide and is characterized by the uncontrolled growth and proliferation of cells. FGF7P3 has been shown to promote the growth and survival of cancer cells, making it a promising target for cancer treatment. Several studies have shown that inhibition of FGF7P3 signaling can lead to significant improvements in the survival rates of cancer patients.

FGF7P3 has also been identified as a potential biomarker for several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and are associated with significant morbidity and mortality. FGF7P3 has been shown to contribute to the development and progression of neurodegenerative diseases, making it a potential diagnostic or therapeutic target.

In addition to its potential clinical applications, FGF7P3 is also a focus of research in the field of neuroscience. The FGF7P3 gene has been shown to play a role in the development and maintenance of neuronal structure and function. FGF7P3 has been shown to promote the migration and survival of neurons, and it has been implicated in the regulation of synaptic plasticity. These findings have significant implications for our understanding of the neuroscience of disease and the potential for therapeutic intervention.

In conclusion, FGF7P3 (KGFLP2) is a protein that has been shown to play a role in several biological processes, including cell growth, differentiation, and survival. The FGF7P3 gene has also been identified as a potential drug target and biomarker for several diseases, including cancer and neurodegenerative diseases. Further research is needed to fully understand the role of FGF7P3 in these conditions and to develop effective therapeutic interventions.

Protein Name: Fibroblast Growth Factor 7 Pseudogene 3

The "FGF7P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FGF7P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets